Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRES… (NCT07298993) | Clinical Trial Compass
By InvitationPhase 4
Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)
United States240 participantsStarted 2026-02-02
Plain-language summary
The goal of this study is to learn whether stopping beta-blockers can help older adults with heart failure with preserved ejection fraction (HFpEF) feel better and function better. This study will test whether "deprescribing" or stopping these medications in a careful, guided way can improve symptoms and quality of life.
Participants will be randomly assigned to one of two groups:
Deprescribing group: Beta-blockers are gradually reduced using capsules that contain decreasing doses.
Usual care group: Beta-blockers are continued at the usual dose in look-alike capsules.
All participants will:
* Take study medicine for about 4 months
* Have their blood pressure and heart rate monitored
* Complete regular phone calls and questionnaires about how they are feeling
This study does not involve any experimental medication. Participants active involvement in the study will last approximately 4 months. During these 4 months they will have 8 scheduled telephone visits.
Who can participate
Age range60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Ambulatory adults age ≥60 years with HFpEF (EF ≥50% based on most recent transthoracic echocardiogram)
✓. Hospitalized with HF in the past 24 months (defined by diagnostic codes in any position)
✓. Taking any of the following ß-blockers: atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate (i.e., pharmacy prescription data)
✓. Kaiser Permanence Northern California Membership
Exclusion criteria
✕. Alternative etiologies of HFpEF syndrome
✕. Compelling guideline indication for ß-blocker:
✕. Evidence of recent decompensated HF
✕. Estimated life expectancy \<6 months (i.e., diagnostic codes)
✕. Diagnosed dementia (i.e.., diagnostic codes)
✕. Unable to provide informed consent
What they're measuring
1
The Hierarchical Composite Endpoint
Timeframe: From baseline (day 0) to end of the follow-up phase (day 120)
Trial details
NCT IDNCT07298993
SponsorWeill Medical College of Cornell University